Publications by authors named "T B Zanoni"
Background: Drug-resistant epilepsy (DRE) secondary to hypothalamic hamartoma (HH) often requires surgical resection or stereotactic radiosurgery, which frequently fail to provide satisfactory outcomes and are associated with severe side effects. Magnetic resonance-guided focused ultrasound (MRgFUS) may represent a minimally invasive surgical approach to HH by offering precise thermal ablation of sub-millimetric brain targets while sparing surrounding structures.
Methods: We present the case of a 19-year-old man with HH-associated DRE, who was successfully treated with MRgFUS.
Liver-on-chip model and application in predictive genotoxicity and mutagenicity of drugs.
Mutat Res Genet Toxicol Environ Mutagen
May 2024
Currently, there is no test system, whether in vitro or in vivo, capable of examining all endpoints required for genotoxicity evaluation used in pre-clinical drug safety assessment. The objective of this study was to develop a model which could assess all the required endpoints and possesses robust human metabolic activity, that could be used in a streamlined, animal-free manner. Liver-on-chip (LOC) models have intrinsic human metabolic activity that mimics the in vivo environment, making it a preferred test system.
View Article and Find Full Text PDFArticle Synopsis
- The text discusses the rising interest in using error-corrected Next Generation Sequencing (ecNGS) as a promising method for assessing mutagenicity, which could eventually replace current testing methods in preclinical safety assessments.
- A workshop held in May 2022 in London brought together experts to share insights on ecNGS advancements, including its correlation with traditional rodent mutation assays and its applications in humans and organoid models.
- The workshop highlighted ecNGS's potential in measuring cancer-related mutations, gene editing effects, and its overall impact on improving drug safety assessments and product development.
Article Synopsis
- A study evaluated the use and effectiveness of intravenous brivaracetam (BRV) in treating status epilepticus (SE) across 24 neurology units in Italy from March 2018 to June 2020.
- Out of 56 patients analyzed, BRV was effective in resolving seizures in 57% of cases, with a notable early response (within 6 hours) observed in 39% of patients.
- The findings suggest that BRV is a safe and beneficial treatment for SE, especially when administered early after the onset of seizures.
Epileptic seizures of suspected autoimmune origin: a multicentre retrospective study.
J Neurol Neurosurg Psychiatry
November 2020
Objective: To analyse autoantibody status in a well-defined European multicentre cohort of patients with epilepsy of unknown aetiology and to validate the recently proposed Antibody Prevalence in Epilepsy (APE2) and Response to ImmunoTherapy in Epilepsy (RITE2) scores.
Methods: We retrospectively collected clinical and paraclinical data of 92 patients referred to the Neurology Units of Verona and Salzburg between January 2014 and July 2019 with new-onset epilepsy, status epilepticus or chronic epilepsy of unknown aetiology. Fixed and live cell-based assays, tissue-based assays, immunoblot, and live rat hippocampal cell cultures were performed in paired serum/cerebrospinal fluid (CSF) to detect antineuronal and antiglial antibodies.